These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 14158954)

  • 21. [Does lyophilization cause the appearance of a non-specific thromboplastic activity in the blood? Study of the antihemophilic factors A and B].
    DUCOS J; BIERME R
    C R Seances Soc Biol Fil; 1960; 154():808-12. PubMed ID: 13724735
    [No Abstract]   [Full Text] [Related]  

  • 22. Lyophilized cryoprecipitate for children with hemophilia A.
    Nuchprayoon I; Sahasittiwat S; Kittikalayawong A; Chantanakajornfung A
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S293-7. PubMed ID: 12188426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AIDS and preventive treatment in hemophilia.
    Desforges JF
    N Engl J Med; 1983 Jan; 308(2):94-5. PubMed ID: 6216409
    [No Abstract]   [Full Text] [Related]  

  • 24. [Occurrence and behavior of fibrin fibrinogen degradation products in concentrates of factor VIII, cryoprecipitate and dextran precipitate during long-term preservation].
    Kätzel R; Wegner H
    Z Gesamte Inn Med; 1977 Nov; 32(22):603-11. PubMed ID: 602311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bleeding syndrome in thrombin-injected rats deficient in fibrinogen and antihemophilic factor.
    BRAYTON RG; ZUCKER MB
    Proc Soc Exp Biol Med; 1957 Nov; 96(2):418-21. PubMed ID: 13485121
    [No Abstract]   [Full Text] [Related]  

  • 26. High-yield method of production of freeze-dried purified factor VIII by blood banks.
    Smit Sibinga CT; Welbergen H; Das PC; Griffin B
    Lancet; 1981 Aug; 2(8244):449-50. PubMed ID: 6115205
    [No Abstract]   [Full Text] [Related]  

  • 27. Freeze-dried activated substrate for factor VIII assays.
    Margolis J
    Dev Biol Stand; 1987; 67():163-7. PubMed ID: 3111909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Use of freeze-dried plasma in the management of bleeding in a child with hemophilia in Djibouti].
    Maurin O; Boulesteix G; Eve O; Bertani A; Martinaud C; Kaiser E
    Ann Fr Anesth Reanim; 2012 May; 31(5):491-2. PubMed ID: 22464160
    [No Abstract]   [Full Text] [Related]  

  • 29. [PLASMA TRANSFUSION IN HEMOPHILIA. IX. EXPERIENCE WITH 2-DONOR FIBRINOGEN].
    VAN CREVELD ; MOCHTAR IA; KOPPE JG
    Ned Tijdschr Geneeskd; 1963 Sep; 107():1736-9. PubMed ID: 14050958
    [No Abstract]   [Full Text] [Related]  

  • 30. [Prophylactic treatment of severe forms of hemophilia A with fraction I (AHG) and PAMBA].
    Gaerisch F; Mey U
    Bibl Haematol; 1967; 27():270-7. PubMed ID: 5302128
    [No Abstract]   [Full Text] [Related]  

  • 31. Fibrinogen; with special reference to its preparation and certain properties of the product.
    WARE AG; GUEST MM; SEEGERS WH
    Arch Biochem; 1947 May; 13(2):231-6. PubMed ID: 20240449
    [No Abstract]   [Full Text] [Related]  

  • 32. Experience with FI-O-Ta.
    Pavlovsky A; De Tezanos Pinto M
    Thromb Diath Haemorrh Suppl; 1968; 35():27-34. PubMed ID: 5761071
    [No Abstract]   [Full Text] [Related]  

  • 33. Impaired cell-mediated immunity in patients with classic hemophilia.
    Lederman MM; Ratnoff OD; Scillian JJ; Jones PK; Schacter B
    N Engl J Med; 1983 Jan; 308(2):79-83. PubMed ID: 6216408
    [No Abstract]   [Full Text] [Related]  

  • 34. An in vivo assessment of factor VIII concentrates.
    Rock G; Tittley P; Fuller V
    JAMA; 1985 Aug; 254(6):777-80. PubMed ID: 3925170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T-lymphocyte subpopulations in patients with classic hemophilia treated with cryoprecipitate and lyophilized concentrates.
    Menitove JE; Aster RH; Casper JT; Lauer SJ; Gottschall JL; Williams JE; Gill JC; Wheeler DV; Piaskowski V; Kirchner P; Montgomery RR
    N Engl J Med; 1983 Jan; 308(2):83-6. PubMed ID: 6401196
    [No Abstract]   [Full Text] [Related]  

  • 36. ASSAY OF FACTOR V ACTIVITY.
    PITNEY WR
    Nature; 1964 Mar; 201():1234. PubMed ID: 14151387
    [No Abstract]   [Full Text] [Related]  

  • 37. Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates.
    Goudemand J
    Haemophilia; 2007 Dec; 13 Suppl 5():47-51. PubMed ID: 18078397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the intensity and quality of treatment and not only the factor VIII level influence global hemostasis in patients with hemophilia A?
    Berndtsson M; Zetterberg E; Holmström M; Mahmoud Hourani Soutari N; Mikovic D; Elezovic I; Antovic JP
    Thromb Res; 2016 Aug; 144():133-5. PubMed ID: 27331346
    [No Abstract]   [Full Text] [Related]  

  • 39. [Results of in vivo analysis of injected fibrinogen degradation products and factor VIII in patients with hemophilia A].
    Kätzel R; Kubel M; Scheel H; Wegner H
    Z Gesamte Inn Med; 1978 Aug; 33(15):525-9. PubMed ID: 695793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in hemophilia.
    Tann G
    Southeast Asian J Trop Med Public Health; 1979 Jun; 10(2):218-28. PubMed ID: 524146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.